drugset / Trial / NCT01174537

New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma

NCT01174537 ↗

Phase 1/2 Withdrawn Hadassah Medical Organization
NaSingle-groupOpen-labelTreatment

Summary

Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression. The study will measure progression-free disease and posits that it will be extended.

Timeline

Start
2011-07
Primary completion
2011-07
Completion
2011-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject New Castle Disease Virus Unknown 1e+10 unknown Intravenous